Centre Brings Gene Therapies, Stem Cell Treatments Under Unified National Regulatory Framework
Until now, the CLAA framework covered selected categories such as vaccines, large-volume parenterals and recombinant DNA (r-DNA)-based medicines.
With the latest amendment, the regulatory umbrella has been extended to include some of the fastest-evolving areas of modern medicine.
New Delhi: In a major regulatory reform aimed at strengthening oversight of next-generation healthcare technologies, the Centre has amended the Drugs Rules, 1945 to bring cell and stem cell-derived products, gene therapies and xenografts under a unified national licensing framework, ensuring uniform regulatory standards across the country.
The amendment expands the scope of the Centrally License Approving Authority (CLAA) framework, placing advanced medical products under the joint supervision of Central and State regulators. The move is expected to enhance patient safety while supporting the responsible adoption of emerging therapies in India’s healthcare system.
Until now, the CLAA framework covered selected categories such as vaccines, large-volume parenterals and recombinant DNA (r-DNA)-based medicines. With the latest amendment, the regulatory umbrella has been extended to include some of the fastest-evolving areas of modern medicine.
Among the newly covered products are cell and stem cell-derived therapies, including regenerative medicine and CAR-T cell therapies used in the treatment of blood cancers such as leukaemia and lymphoma. The framework also includes gene therapeutic products, such as gene replacement and gene-editing technologies used to treat inherited genetic disorders and several forms of cancer.
The revised rules further cover xenografts—medical products derived from animal tissues, including heart valves and other implantable biological materials used in cardiology and orthopaedic procedures.
The government said these advanced technologies require stronger regulatory oversight because of their complexity, specialised nature and rapid scientific evolution. The new framework is intended to establish consistent regulatory standards across states while aligning India’s approval system with global best practices.
According to the Ministry, the amendment will strengthen scientific evaluation, improve regulatory rigour and create greater confidence in the safe adoption of breakthrough therapies, while supporting innovation in biotechnology, healthcare and life sciences.
The government said the initiative reflects its commitment to safeguarding public health while enabling faster access to cutting-edge medical technologies through a modern regulatory ecosystem.
Key Highlights
- Centre amends Drugs Rules, 1945.
- Gene therapies, stem cell-derived products and xenografts brought under CLAA.
- Joint oversight by Central and State regulators.
- Covers advanced therapies including CAR-T cell treatments and gene-editing technologies.
- Aims to improve patient safety and ensure uniform regulatory standards nationwide.
- Aligns India’s regulatory framework with global scientific best practices.
Why it Matters
This is one of India’s most significant biotechnology regulatory reforms in recent years. As advanced therapies such as regenerative medicine, gene editing and personalised cancer treatments become more common, the government is strengthening the regulatory architecture needed to evaluate their safety, quality and effectiveness. The move is expected to support innovation while building public confidence in emerging healthcare technologies.
